Back to search

Article

Two Survival Cuts, One Silent Substitution: The Lurbinectedin Joint Clinical Assessment

2026-08-25

Abstract excerpt

This methodological commentary examines the Joint Clinical Assessment (JCA) report of lurbinectedin combined with atezolizumab as maintenance therapy for extensive-stage small-cell lung cancer, based on the phase 3 IMforte trial. The JCA's evaluation rests on two overall survival data cuts: a confirmatory, hypothesis testing, statistically significant interim cut (hazard ratio 0.73, p=0.0174) and a mature, hypothe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c7241f44-65b6-57f3-a89f-4a6023e75bd0
DOI
10.20944/preprints202608.1708.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Two Survival Cuts, One Silent Substitution: The Lurbinectedin Joint Clinical AssessmentDOI 10.20944/preprints202608.1708.v1
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.Semantic proximity
Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations A case Study using Lung-MAP S1400ISemantic proximity
An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in OncologySemantic proximity
Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations.Semantic proximity
Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible DocumentationSemantic proximity
External Control Arm with Synthetic Real-world Data for Comparative Oncology using Single Trial Arm Evidence (ECLIPSE): A Case Study using Lung-MAP S1400ISemantic proximity
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.Semantic proximity
The R.O.A.D. to clinical trial emulationSemantic proximity
Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.Semantic proximity
Exploring scalable assessment methods for terminated trials in ClinicalTrials.gov: A cohort analysis of German and Californian trialsSemantic proximity
An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib.Semantic proximity
Select a neighboring publication to make it the new centre.